TABLE 5.
Pharmacometric parameters of artesunate and dihydroartemisinin after intravenous and rectal administration of artesunate in children with severe malaria
| Parametere | Value(s) [median (IQR)] by route of administration |
|
|---|---|---|
| Intravenous | Rectal | |
| Analyzed, n | 80 | 80 |
| Artesunate | ||
| tmax (h) | 0.083 (0.083–0.100) | 0.500 (0.250–0.750) |
| Cmax (nM) | 6,660 (3,770–13,500) | 442 (213–813) |
| Cmax/D (nM/μmol) | 71.0 (40.6–99.1) | 2.08 (1.05–4.26) |
| tlast (h) | 3.00 (2.00–6.00) | 6.00 (4.00–8.00) |
| AUCt/D (h·nM/μmol) | 10.2 (5.92–14.0) | 2.57 (1.68–4.57) |
| t1/2 (h) | 0.571a (0.299–1.08) | 0.525b (0.325–0.770) |
| F (%) | 25.6 (11.7–54.5) | |
| Dihydroartemisinin | ||
| tmax (h) | 0.250 (0.083–0.250) | 1.00 (0.750–2.00) |
| Cmax (nM) | 5,100 (3,850–5,860) | 1,800 (822–3,100) |
| Cmax/D (nM/μmol) | 40.8 (28.6–74.3) | 3.34 (1.88–6.44) |
| tlast (h) | 8.00 (6.00–8.00) | 8.00 (7.89–8.00) |
| AUCt/D (h·nM/μmol) | 37.4 (24.3–61.2) | 6.97 (3.94–14.5) |
| t1/2 (h) | 0.882c (0.686–1.19) | 0.865d (0.681–1.18) |
| F (%) | 19.8 (10.3–35.3) | |
a
One individual was excluded from the analysis due to a lack of data in the elimination phase.
b
Six individuals were excluded from the analysis due to a lack of data in the elimination phase.
c
One individuals were excluded from the analysis due to a lack of data in the elimination phase.
d
Seven individuals were excluded from the analysis due to a lack of data in the elimination phase.
e
D, dose.